New Drug Combination Offers Hope for Acute Myeloid Leukemia Patients

A research team at Oregon Health & Science University has unveiled a promising drug combination that could enhance treatment for patients suffering from acute myeloid leukemia (AML). This breakthrough, detailed in a recent study published in Cell Reports Medicine, demonstrates that pairing venetoclax, a frontline therapy for AML, with palbociclib, a cell-cycle inhibitor approved for breast cancer, significantly improves anti-leukemia activity.

The study analyzed over 300 patient samples and confirmed that the combination therapy not only provides a stronger response than venetoclax alone but also offers a more durable solution against drug resistance. This finding was validated through tests on human tissue samples and mouse models carrying human leukemia cells.

Dr. Melissa Stewart, research assistant professor at OHSU and lead author of the study, stated, “Of the 25 drug combinations tested, venetoclax plus palbociclib was the most effective.” She emphasized the importance of understanding why this combination works so well and how it can overcome challenges presented by existing therapies.

### Drug Resistance in AML Treatment

Acute myeloid leukemia remains a significant health concern, with more than 20,000 Americans diagnosed each year. Despite the approval of venetoclax in 2019, which has improved initial treatment outcomes, the issue of drug resistance persists. Dr. Jeffrey Tyner, professor of cell, developmental, and cancer biology at OHSU, highlighted that nearly all patients will eventually experience some form of resistance to treatment.

“While this regimen has enhanced response rates and quality of life, the five-year survival rate for AML remains around 25% to 40%,” Tyner noted. He co-leads the national Beat AML 1.0 program, which aims to innovate treatment strategies for this aggressive leukemia type. The new study builds on findings from this initiative, validating the potential of the venetoclax and palbociclib combination.

### Mechanism of Action

The study revealed that AML cells often adapt to venetoclax treatment by increasing protein production, which helps them survive. The addition of palbociclib disrupts this adaptation mechanism by regulating the cell’s protein-production processes. Stewart remarked, “Patient samples that responded strongly to the combination showed clear downregulation of genes involved in protein synthesis. This was a big clue.”

Further investigations using a genome-wide CRISPR screen indicated that while venetoclax alone benefits from the loss of protein-production genes, the combination therapy does not depend on this vulnerability, suggesting that the drugs work together to inhibit multiple survival pathways.

In experiments with mouse models engineered to carry mutations associated with venetoclax resistance, the results were striking. “In this model, venetoclax alone didn’t extend survival at all,” Stewart explained. “But with the combination, the majority of mice lived between 11 to 12 months, and one mouse remained alive at the conclusion of the study.”

### Personal Motivation and Future Directions

Stewart shared a personal connection to the research, stating, “As a breast cancer survivor treated at OHSU, I understand the experience of being a cancer patient. The hope that research and clinical trials can bring is what drives my work.” Both Stewart and Tyner stressed the significance of following scientific data, even when it leads to unconventional avenues of research.

Tyner remarked, “Some might wonder why a breast cancer drug would be effective in AML. Biology can be shared across different cancers, illustrating the importance of maintaining an open mind.” The researchers are also exploring other drugs similar to palbociclib, aiming to broaden future clinical trial options.

While the combination has not yet been tested in patients, Tyner remains optimistic. “Based on our findings, we predict that this combination would mitigate most known resistance mechanisms to current standard therapies,” he stated. “Transforming this into a clinical reality will require considerable effort, but this is precisely why we conduct this research.”

As the scientific community continues to address the challenges of AML, this innovative drug combination offers a glimmer of hope for improving treatment outcomes for patients facing this aggressive disease.